Literature DB >> 16292350

Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.

H Kamiyama1, G Zhou, B Roizman.   

Abstract

Earlier this laboratory constructed a herpes simplex virus 1 recombinant (R5111) that carries a IL13 ligand inserted into glycoprotein D and can enter cells via the IL13Ralpha2 receptor commonly expressed on the surface of malignant glioma cells. In this report, we describe the properties of two recombinant viruses carrying chiemric gD genes. In R5181 recombinant virus the chimeric gene consisted on the residues 20-155 of urokinase plaminogen activator (uPA) inserted between residues 24 and 25 of gD. In R5182 the insert consisted of a 23-residue sequence encoding the uPA binding domain for the urokinase plaminogen activator receptor (uPAR). These viruses were constructed for three reasons, to increase the number of viruses that specifically target receptors on the surface of malignant glioma cells, to determine whether viruses exhibiting novel ligands could enter cells via receptors anchored to the cell surface via glycosylphosphatidylinositol anchor as has been recently demonstrated for nectin1, and to determine whether receptors other than IL13Ralpha2 could be targeted by genetic engineering of the virus. We report that R5181 but not R5182 recombinant virus was able to enter cells expressing uPAR. The results indicate that HSV-1 recombinant viruses can be engineered to enter cells via a variety of unrelated nonviral receptors, including receptors that are anchored to the cells surface but without transmembrane domains.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16292350     DOI: 10.1038/sj.gt.3302685

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  25 in total

1.  Separation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins.

Authors:  Guoying Zhou; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

Review 2.  Targeted entry of enveloped viruses: measles and herpes simplex virus I.

Authors:  Chanakha K Navaratnarajah; Tanner S Miest; Andrea Carfi; Roberto Cattaneo
Journal:  Curr Opin Virol       Date:  2011-12-23       Impact factor: 7.090

3.  A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors.

Authors:  Laura Menotti; Arianna Cerretani; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.

Authors:  Clemens Busse; Regina Feederle; Martina Schnölzer; Uta Behrends; Josef Mautner; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

Review 5.  New viruses for cancer therapy: meeting clinical needs.

Authors:  Tanner S Miest; Roberto Cattaneo
Journal:  Nat Rev Microbiol       Date:  2013-12-02       Impact factor: 60.633

Review 6.  Retargeting of herpes simplex virus (HSV) vectors.

Authors:  William F Goins; Bonnie Hall; Justus B Cohen; Joseph C Glorioso
Journal:  Curr Opin Virol       Date:  2016-09-08       Impact factor: 7.090

7.  Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.

Authors:  Laura Menotti; Arianna Cerretani; Hartmut Hengel; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

8.  Cross talk among the glycoproteins involved in herpes simplex virus entry and fusion: the interaction between gB and gH/gL does not necessarily require gD.

Authors:  Elisa Avitabile; Cristina Forghieri; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

9.  Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor.

Authors:  Guoying Zhou; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-22       Impact factor: 11.205

Review 10.  Herpes simplex virus oncolytic therapy for pediatric malignancies.

Authors:  Gregory K Friedman; Joseph G Pressey; Alyssa T Reddy; James M Markert; G Yancey Gillespie
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.